Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis.
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Pediatric multiple sclerosis.
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Increased axonal expression of nectin-1 in multiple sclerosis plaques.
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Calcitriol Modulates the CD46 Pathway in T Cells.
Substance Name: Amiloride
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Laquinimod Phase IIa Study in Active Crohn's Disease
Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Puma, but not noxa is essential for oligodendroglial cell death.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.

Pages